Editas Medicine Inc
NASDAQ:EDIT
Editas Medicine Inc
Pre-Tax Income
Editas Medicine Inc
Pre-Tax Income Peer Comparison
Competitive Pre-Tax Income Analysis
Latest Figures & CAGR of Competitors
Company | Pre-Tax Income | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Editas Medicine Inc
NASDAQ:EDIT
|
Pre-Tax Income
-$153.2m
|
CAGR 3-Years
-10%
|
CAGR 5-Years
-7%
|
CAGR 10-Years
N/A
|
|
Abbvie Inc
NYSE:ABBV
|
Pre-Tax Income
$6.3B
|
CAGR 3-Years
23%
|
CAGR 5-Years
4%
|
CAGR 10-Years
2%
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Pre-Tax Income
$1.1B
|
CAGR 3-Years
-18%
|
CAGR 5-Years
-33%
|
CAGR 10-Years
-16%
|
|
Amgen Inc
NASDAQ:AMGN
|
Pre-Tax Income
$7.9B
|
CAGR 3-Years
-1%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
4%
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Pre-Tax Income
$4.4B
|
CAGR 3-Years
12%
|
CAGR 5-Years
49%
|
CAGR 10-Years
N/A
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Pre-Tax Income
$4.2B
|
CAGR 3-Years
3%
|
CAGR 5-Years
10%
|
CAGR 10-Years
19%
|
See Also
What is Editas Medicine Inc's Pre-Tax Income?
Pre-Tax Income
-153.2m
USD
Based on the financial report for Dec 31, 2023, Editas Medicine Inc's Pre-Tax Income amounts to -153.2m USD.
What is Editas Medicine Inc's Pre-Tax Income growth rate?
Pre-Tax Income CAGR 5Y
-7%
Over the last year, the Pre-Tax Income growth was 30%. The average annual Pre-Tax Income growth rates for Editas Medicine Inc have been -10% over the past three years , -7% over the past five years .